BNA’s Health Care Daily Report™ sets the standard for reliable, high-intensity coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a...
Oct. 17 — The Medicare agency needs to improve its policies for covering new medical technologies, the president and CEO of device maker CVRx said Oct. 17.
The Advanced Medical Technology Association (AdvaMed) also views this as a problem and plans to push Congress and the Centers for Medicare & Medicaid Services to make it easier for manufacturers to get new devices covered, CVRx's Nadim Yared said. Yared is also AdvaMed's board.
He spoke during a press conference at AdvaMed's 2016 conference in Minneapolis. CVRx is a privately held company based in Minneapolis.
At issue is the time lag between a product's approval for the U.S. market and a decision on whether Medicare will cover it. Many in the device industry believe the time between the Food and Drug Administration decision on a new device's safety and efficacy and when the CMS makes a coverage determination for the product is too long. Acquiring CMS coverage for a new medical device is crucial to a product's success, especially as many private payers partially base their own coverage determinations on what the Medicare agency decides.
An Oct. 17 report sponsored by AdvaMed Accel, an industry group specifically for small device companies and startups, pointed to the need for more predictable coverage decisions from the CMS and other payers.
“Even where coverage is ultimately granted, delays and inconsistencies are a formidable barrier to investment and to start-up company success,” the report said.
The device reimbursement process is complex, Martha Shadan said in the report. Shadan is president and CEO of Rotation Medical, a medical technology company based in Plymouth, Minn.
In fact, the FDA process for getting approval or clearance for a new product seems less complex than getting a payer to make coverage decision, Shadan said. “There are multiple players and the issues are further complicated by regional differences as well as differences in provider contracts with payers,” she added.
The AdvaMed Accel report, which is partly based on anonymous conversations with device industry entrepreneurs and investors, highlighted a desire among some in the industry to tie coverage to FDA determinations on safety and efficacy.
Reimbursement should occur concurrently with FDA approval and/or clearance determinations, the report said. Statements and recommendations in the report aren't necessarily the views of AdvaMed or AdvaMed Accel, the document said.
There's bipartisan support for making such a change in Congress. In April, Reps. Charles Boustany Jr. (R-La.), Gus Bilirakis (R-Fla.), Richard Neal (D-Mass.) and Tony Cardenas (D-Calif.) introduced the Breakthrough Pathways for New Medical Technologies Act (H.R. 5009) (80 HCDR, 4/26/16).
The legislation would immediately extend CMS coverage to so-called breakthrough devices for three years immediately upon the FDA determining the product is safe and effective. The FDA has an established process to identify new breakthrough technologies for serious illnesses and to give them priority review.
The bill has been referred to the health subcommittees of the Ways and Means and Energy and Commerce committees.
To contact the reporter on this story: Michael D. Williamson in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)